MedTrace Logo

Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis

NCT07680738 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-07-02

No results posted yet for this study

Summary

Multiple sclerosis (MS) is a chronic, inflammatory and disabling disease of the Cnetral Nervous System characterized by relapsing and / or progressive somatosensory, motor and vestibular clinical manifestations. Moreover, fatigue, depression, anxiety, and cognitive impairment are also present in most MS patients. These symptoms substantially impact quality of life and often show limited response to conventional pharmacological treatment.

Transcranial direct current stimulation (tDCS) is a non-invasive technique that applies a weak direct current to the scalp via surface electrodes, modulating cortical excitability in a polarity-dependent manner.

The objective of this study is to evaluate the efficacy and safety of tDCS for fatigue, depression, anxiety, and cognitive performance in patients with relapsing or progressive MS.

Conditions

  • Multiple Sclerosis, MS
  • Multiple Sclerosis
  • Multiple Sclerosis (MS) - Relapsing-remitting
  • Multiple Sclerosis (MS) Primary Progressive
  • Fatigue
  • Fatigue in Multiple Sclerosis
  • Transcranial Direct Current Stimulation
  • Non-invasive Brain Stimulation

Interventions

DEVICE

Transcranial Direct Current Stimulation

Transcranial direct current stimulation (tDCS) is a non-invasive technique that applies a weak direct current to the scalp via surface electrodes, modulating cortical excitability in a polarity-dependent manner. tDCS has an established safety profile across the populations and protocols studied to date. This study uses an anodal stimulation montage of the dorsolateral prefrontal cortex (DLPFC).

DEVICE

Sham transcranial direct current stimulation simulation

Sham Comparator: Sham, F3 anode, F4 cathode, 20 minutes, transcranial direct current stimulation simulation

Sponsors & Collaborators

  • Universidad de Almeria

    lead OTHER

Principal Investigators

  • ASDRUBAL R HUERTA GALLANGO, MD / PhD · Universidad de Almeria

  • Luis Fernando Sánchez-Santed, PhD · Universidad de Almeria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-08-30
Completion
2024-08-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07680738 on ClinicalTrials.gov